A

Apontis Pharma AG
XETRA:APPH

Watchlist Manager
Apontis Pharma AG
XETRA:APPH
Watchlist
Price: 9.64 EUR -1.43% Market Closed
Market Cap: 80.3m EUR
Have any thoughts about
Apontis Pharma AG?
Write Note

Apontis Pharma AG
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Apontis Pharma AG
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
A
Apontis Pharma AG
XETRA:APPH
Accumulated Depreciation
-€659.2k
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ATAI Life Sciences NV
NASDAQ:ATAI
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bayer AG
XETRA:BAYN
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck KGaA
XETRA:MRK
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dermapharm Holding SE
XETRA:DMP
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PharmaSGP Holding SE
XETRA:PSG
Accumulated Depreciation
-€381k
CAGR 3-Years
-92%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
No Stocks Found

Apontis Pharma AG
Glance View

Market Cap
80.3m EUR
Industry
Pharmaceuticals

APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.

APPH Intrinsic Value
15.03 EUR
Undervaluation 36%
Intrinsic Value
Price
A

See Also

What is Apontis Pharma AG's Accumulated Depreciation?
Accumulated Depreciation
-659.2k EUR

Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Accumulated Depreciation amounts to -659.2k EUR.

What is Apontis Pharma AG's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 3Y
-6%

Over the last year, the Accumulated Depreciation growth was -3%. The average annual Accumulated Depreciation growth rates for Apontis Pharma AG have been -6% over the past three years .

Back to Top